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Abstract Lymphatic distribution of interstitially injected po-
loxamer 407-coated nanospheres (45 nm in diameter) is con-
trolled by surface con¢guration of the ethylene oxide (EO) seg-
ments of the adsorbed copolymer. At low poloxamer surface
coverage, EO tails spread laterally on a nanosphere surface
and assume a ‘£at or mushroom-like’ con¢guration. Such enti-
ties drain rapidly from the subcutaneous site of injection into the
initial lymphatic, when compared to uncoated nanospheres, and
subsequently are captured by scavengers of the regional lymph
nodes. In vitro experiments have also con¢rmed that such enti-
ties are prone to phagocytosis. When the equilibrium poloxamer
concentration is at 75 Wg/ml or greater the EO chains become
more closely packed and project outward from the nanosphere
surface. These surface-engineered nanospheres drain faster than
those with EO chains in mushroom con¢gurations into the initial
lymphatic, escape clearance by lymph node macrophages, reach
the systemic circulation, and remain in the blood for prolonged
periods. These experiments provide a rational approach for the
design and engineering of nano-vehicles for optimal lymphatic
targeting and are discussed.
0 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The thin-walled and fenestrated lymphatic microvessel is
easily penetrated by colloidal particles after injection into
the extracellular space [1]. Once inside the vessel, particles
that are transported with lymph are usually cleared by macro-
phages located in the lymph nodes [1]. These means of partic-
ulate transportation and clearance mechanisms can be taken
into clinical advantage. For example, interstitial delivery of
colloidal diagnostic agents has been of bene¢t in determin-
ing regional spread of cancer and assessing lymphatic func-
tion either by lymphoscintigraphy or indirect lymphography
[2^5].
The behaviour of particles following interstitial administra-
tion is controlled by a number of physicochemical and bio-
logical factors [2]. Physicochemical considerations include par-
ticle size and their surface characteristics [1,2,6^8]. Generally,
the size of the particles must be larger than 20 nm to prevent
their leakage into the blood capillaries. Although larger par-
ticles (s 100 nm) may carry a considerable amount of ther-
apeutic or diagnostic agents they move very slowly from the
site of injection into initial lymphatics ; the drainage often
takes a number of days [2]. This slow transit may induce local
in£ammation and renders particles susceptible to phagocytosis
or macropinocytosis at the injection site. Even the movement
of small particles (20^100 nm range) from the interstitial sites
into regional lymph nodes is generally slow and uptake values
hardly exceed 10% of the administered dose even 24 h post
injection [1,2]. This is usually due to particle aggregation and/
or interaction with the ground substance of interstitium [1].
Previous work initiated by the author [7] demonstrated that
by using the concept of steric stabilisation one could success-
fully control the rate of particle drainage from the subcuta-
neous injection site and manipulate their lymphatic distribu-
tion. For example, steric stabilisation of model polystyrene
nanoparticles can be achieved by surface coating with polox-
amers, which are ABA type block copolymers [9]. The ‘A’
segment is comprised from ethylene oxide (EO) units, whereas
the central ‘B’ region is formed from propylene oxide (PO)
units. The longer the EO chain of the poloxamers (while
maintaining the length of the hydrophobic PO segment), the
less tendency there is for particle aggregation as well as inter-
action with the interstitial elements. This results in rapid par-
ticle drainage into the initial lymphatics [7]. In addition, the
length of the EO chain was shown to control the extent of
particle^macrophage interaction. For example, the strong ste-
ric barrier of poloxamer 407, which arises from 98 EO units
per chain, suppresses particle opsonisation in lymph and/or
interaction with macrophage receptors [7]. Such engineered
entities drain rapidly into the initial lymphatics, escape clear-
ance by lymph node macrophages, reach the systemic cir-
culation, and remain in the blood for prolonged periods of
time [7]. To enhance simultaneously both rapid particle drain-
age from interstitium and capture by regional lymph node
macrophages, particles require coating with poloxamers con-
taining 4^15 EO units per chain (e.g. poloxamers 401 and 402)
[7].
In view of these ¢ndings, it is imperative to further examine
the relationship between physicochemical properties of polox-
amer-coated nanoparticles and their lymphatic distribution
and establish requirements for optimal targeting. Therefore,
this manuscript examines the e¡ect of surface density and the
resultant con¢guration of the EO chains of the poloxamers on
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the extent of drainage and lymphatic distribution of model
polystyrene nanoparticles following interstitial injection.
2. Materials and methods
2.1. Particles and surface modi¢cation procedures
Polystyrene nanospheres, 45.4K 0.7 nm (polydispersity index
0.08K 0.01), manufactured by Polysciences (USA) were obtained
from Park Scienti¢c (Northampton, UK) and surface-labelled with
Na[125I] (Amersham Pharmacia Biotech, UK) by a radiation-induced
bonding of idoine as described in detail previously [7,10]. The labelled
particles were cleaned by dialysis prior to surface modi¢cation with
copolymers. Poloxamers 401, 402 and 407 (Table 1) were the kind
gifts of BASF (Mt. Olive, NJ, USA) and were dissolved in 10 mM
McIlvaine bu¡er, pH 7.2. In accordance with previous experiments [7]
nanospheres were coated by preincubation in a 0.1% (w/v) solution of
various poloxamers at room temperature overnight. The equilibrium
concentration of poloxamers used in nanosphere coating (0.1% w/v) is
well above the ¢nal plateau region of their respective adsorption iso-
therm [7]. In some experiments, nanospheres were incubated with
di¡erent concentrations of poloxamer 407 in order to achieve di¡erent
percentages of surface coverage at points below the top plateau region
of the adsorption isotherm (the top plateau of the adsorption iso-
therm is reached at an equilibrium poloxamer concentration of 180^
210 Wg/ml at 25‡C with the designated batch of nanospheres). The
adsorbed layer thickness of poloxamers on polystyrene nanospheres
was measured by photon correlation spectroscopy, using a Zetasizer
3000 (Malvern Instruments, UK), in 10 mM McIlvaine bu¡er, pH 7.2,
at 24‡C as described in detail elsewhere [11]. Brie£y the measurements
were determined at a wavelength of 633 nm, scattering angle of 90‡,
dispersant viscosity of 0.89 cP and refractive index of 1.35.
2.2. Lymphatic distribution studies
Groups of three male Wistar rats, body weight 150K 10 g, were
injected subcutaneously into the dorsal surface of the left footpad
with either uncoated or poloxamer-coated polystyrene nanospheres
(in a total volume of 100 Wl containing 0.1 mg polystyrene nanopar-
ticles). Rats were sacri¢ced either at 2 or 6 h post injection and the
nanosphere-associated radioactivity was measured in the footpad
(whole foot), regional lymph nodes (whole popliteal or primary, and
iliac or secondary nodes), blood and organs of the reticuloendothelial
system, RES, (liver and spleen) using a gamma counter. Due to mac-
rophage heterogeneity the whole liver and spleen were counted for
radioactivity. No radioactivity was detected in the right footpad (der-
mal region) and its associated regional lymph nodes. To determine the
amount of radioactivity in the blood, a total blood volume per rat of
7.0% of body weight was assumed [12]. The correction factor for the
blood content of the injected footpad was determined by subtracting
the amount of radioactivity associated with the non-injected footpad.
The correction factor for the blood content in the liver and the spleen
was determined as previously [12].
2.3. Nanosphere uptake by peritoneal macrophages
Resident peritoneal macrophages were obtained by washing the
peritoneal cavity of rats with Hanks’ balanced salt solution (HBSS),
followed by centrifugation at 150Ug, 5 min [13]. Contaminating red
cells were lysed by Tris-ammonium chloride bu¡er (pH 7.2) [13]. Cells
were washed twice in HBSS and resuspended in the same bu¡er.
Macrophages were plated in 48-well tissue culture dishes at a density
of 5U105 cells per well in HBSS containing 10% v/v foetal calf serum.
After 24 h incubation at 37‡C, 125I-labelled polystyrene nanospheres
of di¡erent surface characteristics (1010 particles) were added and the
cells were left to incubate for an additional 3 h. Prior to cell incuba-
tion, free poloxamer molecules were removed from the nanoparticle
suspensions by centrifugation at 200 000Ug for 30 min and subse-
quent washings. All incubations with polystyrene nanoparticles con-
tained 10% v/v serum, thus to account for possible opsonisation
events [11]. At the end of the incubation, cells were washed three
times with HBSS, then solubilised with KOH. The total radioactivity
associated with cell lysate was determined using a gamma counter.
For each nanoparticle type triplicate incubations were performed.
Uptake of uncoated nanoparticles was considered as 100%. The re-
sults of polymer-treated nanospheres are expressed as % uptake of
uncoated particles.
3. Results and discussion
The data in Table 2 demonstrate the adlayer thickness of
poloxamers on polystyrene nanospheres as well as the lym-
phatic localisation of polymer-coated nanospheres following
interstitial injection into rat footpad. It has generally been
accepted that the surface density of the adsorbed block co-
polymers can a¡ect polymer con¢guration, e.g. ‘mushroom’
versus ‘brush’ con¢gurations [11,14,15]. In addition, the thick-
ness of the coating layer can re£ect surface con¢guration of
the adsorbed or grafted polymers on nanoparticles [11,14^17].
Since the equilibrium concentration of the poloxamers used in
Table 2 for the surface modi¢cation of nanospheres is in the
plateau region of their respective adsorption isotherm [7], the
EO chains are thought to project from the surface of polysty-
rene nanospheres and assume ‘mushroom-brush’ intermediate
and/or ‘brush-like’ con¢guration(s) [11,14,15]. Although, the
fastest drainage from the injection site into the initial lym-
phatic occurs with the poloxamer 407-coated systems, nano-
sphere capture by lymph node is minimal even at 6 h post
injection. Conversely, the rate of drainage is considerably
slower with poloxamer 401- and 402-coated systems, but par-
ticle capture by regional nodes is maximised. In contrast, the
bulk of uncoated nanospheres remain at the injection site. The
di¡erential biodistribution of particles is due to the extent of
Table 1
Structure of the A1-B-A2 type block copolymers (A1=A2)
Poloxamer type A1 block B block A2 block
(EO units) (PO units) (EO units)
Poloxamer 401 5 67 5
Poloxamer 402 11 67 11
Poloxamer 407 98 67 98
Table 2
Biodistribution of uncoated and poloxamer-coated polystyrene nanospheres following subcutaneous injection
Coating Coating thickness Sacri¢ce time (h) Distribution (% of injected dose)
Footpad 1‡ node 2‡ node RES Blood
None ^ 2 79.3K 3.2 1.7 K 0.6 0.8 K 0.2 0.2 K 0.1 0.2K 0.1
6 71.6K 2.8 3.8 K 0.2 1.2 K 0.1 0.1 K 0.1 0.2K 0.1
401 1.40 nm 2 64.3K 1.7 13.9K 2.8 4.6 K 1.1 2.9 K 0.3 1.2K 0.6
6 51.7K 3.6 16.3K 1.7 8.8 K 1.3 5.3 K 0.3 0.4K 0.1
402 2.59 nm 2 60.8K 3.7 17.6K 3.6 8.2 K 1.9 1.7 K 1.0 0.9K 0.2
6 48.7K 1.9 19.6K 1.3 14.3K 2.6 2.1 K 0.6 0.8K 0.3
407 8.84 nm 2 34.5K 1.6 0.7 K 0.4 0.2 K 0.1 2.6 K 0.1 49.6K 2.1
6 13.7K 0.8 0.5 K 0.1 0.2 K 0.1 4.4 K 0.7 60.3K 2.5
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surface opsonisation or direct interaction with macrophage
receptors, and these are controlled by the e⁄cacy of the im-
posed steric barrier of the poloxamer EO chains, as discussed
previously [7]. Unlike the uncoated system, where the major
site of nanosphere accumulation in the regional lymphatic is
the primary lymph node (popliteal node), surface coating with
both poloxamers 401 and 402 further enhances particle reten-
tion in the secondary (illiac) node (Table 2). Therefore, it
appears that for rapid and e¡ective lymph node targeting
the projected thickness of the coating polymer should not
exceed 3.0 nm (as in the case of poloxamer 402-coated nano-
spheres).
On the basis of the above suggestions it should be possible
to simultaneously enhance the drainage of poloxamer 407-
coated particles from the subcutaneous injection site and their
retention in regional lymph nodes. This could be achieved if
the adlayer thickness of poloxamer 407 on the surface of poly-
styrene nanospheres is adjusted to 1.5^2.5 nm (a thickness
layer similar to those of poloxamers 401 and 402, see Table
2). Therefore, the adlayer thickness of poloxamer 407 on poly-
styrene nanospheres as a function of the equilibrium polox-
amer concentration was examined. The data in Fig. 1 demon-
strate that the adlayer thickness of poloxamer 407 on
polystyrene nanospheres increases with increasing the equilib-
rium polymer concentration and is in accordance with the
previous suggestions of Baker and Berg [14]. The thickness
rises rapidly at low concentrations and levels o¡ at bulk poly-
mer concentrations corresponding to the plateau adsorption
coverage (the adsorption isotherm is not shown). These ob-
servations indicate changes in con¢guration of the EO chains
with increasing polymer concentration. At low surface cover-
age, EO tails are less densely packed and gyrate although,
eventually ¢nding bare patches on the particle surface causing
them to spread laterally assuming a ‘£at or mushroom-like’
con¢guration [16]. This mode of adsorption explains why the
adlayer thickness values are very low (less than 3.5 nm) at
equilibrium poloxamer concentrations below 0.05 mg/ml. In-
terestingly, the measured adlayer thickness of poloxamer 407
on nanospheres at polymer concentrations below 0.05 mg/ml
is very similar to those of poloxamers 401 and 402, where the
equilibrium polymer concentration was in the plateau region
of the adsorption isotherm (Table 2). Next, the lymphatic
distribution of nanospheres was tested following interstitial
injection. Remarkably, the extent of drainage and lymph
node localisation of particles pre-coated with poloxamer 407
at concentrations below 0.05 mg/ml are similar to those of
poloxamer 401- or 402-coated nanospheres both at 2 and 6 h
post injection (Table 3). These observations suggest that the
EO chains of poloxamer 407 in ‘£at or mushroom’ con¢gura-
tion are not only e¡ective in suppressing nanosphere aggrega-
tion at the interstitial sites, but also the assumed con¢guration
fails to e⁄ciently camou£age particles against macrophage
recognition. It should be emphasised that similar observations
are obtained with poloxamer 401 and 402 but with EO chains
in a brush-like con¢guration (Table 2). Therefore, it seems
that partial surface coverage (in the region of 11^15% of total
surface area) with poloxamer 407 is su⁄cient to minimise
nanoparticle aggregation at interstitial sites and simultaneous-
ly enhance clearance by lymph node scavengers. This state-
ment is further supported by in vitro experiments with peri-
toneal macrophages, as these cells were able to recognise
poloxamer-coated particles with EO chains in a predomi-
nantly mushroom con¢guration (Fig. 2). However, these par-
ticles are recognised signi¢cantly to a lesser extent than their
uncoated counterparts, and this further supports the presence
of the relatively hydrophilic EO chains in close proximity to
the surface. These observations are also in agreement with a
recent report from this laboratory where microspheres coated
with methoxypoly(ethylene glycol)-5000 in a mushroom regime
were found to be prone to phagocytosis in vitro [11].
As the equilibrium concentration of poloxamer 407 in-
creases, the thickness of the adsorbed layer also increases
(Fig. 1) [14,15]. This is believed to be due to repulsion between
EO and PO chains [16]. The repulsion causes EO chains to
desorb from the surface and assume ‘mushroom-brush’ inter-
mediate and/or ‘brush-like’ con¢guration(s) [16]. Such surface
Fig. 1. Adlayer thickness of poloxamer 407 on polystyrene nanopar-
ticles as a function of the equilibrium poloxamer concentration.
Table 3
The e¡ect of equilibrium concentration of poloxamer 407 on biodistribution of subcutaneously injected polystyrene nanospheres
[Polymer] (mg/ml) Coating thickness Sacri¢ce time (h) Distribution (% of injected dose)
Footpad 1‡ node 2‡ node RES Blood
None ^ 2 82.1K 3.2 1.4K 0.2 0.4 K 0.1 0.2 K 0.1 0.2 K 0.1
6 76.3K 2.8 2.8K 0.7 1.1 K 0.1 0.2 K 0.1 0.1 K 0.1
0.025 1.85 nm 2 57.4K 3.9 15.6K 1.7 10.2K 2.1 4.3 K 1.1 1.1 K 0.4
6 45.3K 1.9 17.3K 1.1 13.4K 0.9 5.1 K 0.2 0.9 K 0.1
0.050 3.20 nm 2 50.3K 2.7 11.1K 3.3 8.8 K 1.9 5.2 K 0.2 0.9 K 01
6 39.6K 1.9 12.6K 1.2 13.3K 0.7 7.3 K 0.6 0.8 K 0.3
0.075 3.92 nm 2 42.9K 3.2 3.2K 1.5 2.8 K 1.9 7.7 K 1.2 32.1K 2.3
6 19.6K 1.7 4.1K 0.6 3.1 K 0.2 10.2K 2.1 45.6K 2.1
0.100 5.40 nm 2 36.3K 1.8 0.7K 0.6 0.3 K 0.2 2.1 K 0.2 50.2K 2.4
6 11.8K 0.9 0.8K 0.4 0.3 K 0.1 3.1 K 0.4 66.1K 1.3
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con¢gurations are highly e¡ective in preventing particle aggre-
gation at the injection site as well as particle capture by lymph
node scavenger cells. The e¡ect is observed at an equilibrium
poloxamer 407 concentration of 0.075 mg/ml, corresponding
to an adlayer thickness of 3.92 nm (Table 3). The relationship
between the adlayer thickness (hence, the EO con¢guration)
and phagocytosis is further illustrated by in vitro experiments
where nanoparticles with surface EO chains in brush con¢g-
uration show resistance to macrophage recognition (Fig. 2).
In summary, this work has established an interesting corre-
lation between the surface characteristics of colloidal particles
and their lymphatic distribution. By controlling the surface
con¢guration of the EO segments of poloxamers, and hence
the adlayer thickness, or vice versa, the lymphatic distribution
of sterically stabilised particles can be modulated (e.g., lym-
phoscintigraphic tracing versus lymph node mapping). The
described relationship between surface properties of nanopar-
ticles and their biodistribution provides a simple but a ration-
al means for the design and engineering of lymphotropic en-
tities, rather than choosing coating materials on a random
basis [18]. Therefore, this report for the ¢rst time shows
that a stealth polymeric coating can be used to design carrier
systems that can be targeted e⁄ciently and rapidly to the
desired lymph node elements (for drug delivery or medical
imaging) following interstitial injection. These suggestions
may also be applicable to liposome engineering for lymphatic
targeting. Incorporation of 5^7 mol% monomethoxypoly-
(ethyleneglycol)2000-phosphatidylethanolamine (mPEG2000-PE)
into liposomal lipid bilayer is known to dramatically enhance
the drainage of interstitially injected vesicles into the initial
lymphatics [6,19]. However, such vesicles are recognised
poorly by scavengers of the regional lymph nodes and are
passed into the blood stream [19]. Based on measurements
of ultrasound velocity and absorption in liposome suspensions
it appears that at a concentration of 5^7 mol% mPEG2000-PE,
the surface grafted mPEG2000 assumes an intermediate mush-
room-brush conformation, whereas at lower concentrations
(up to 4 mol%) the surface PEG molecules display a non-
overlapped mushroom regime [20]. Therefore, to optimise
the lymphatic targeting of sterically stabilised liposomes a
combination of an appropriate quantity of mPEG-lipid (up
to 4 mol%) and targeting ligand (e.g. mannose or antibodies
grafted to phospholipids or to the distal end of PEG mole-
cules) is proposed.
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Fig. 2. Interaction of nanoparticles with rat peritoneal macrophages.
Uptake of uncoated nanoparticles is considered as 100%. The results
of poloxamer-coated nanoparticles are expressed as % uptake of un-
coated nanoparticles.
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